We have observed
12 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after August 17, 2014).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
NEW FORMS AND SALTS OF A DIHYDROPYRROLO[1,2-C]IMIDAZOLYL ALDOSTERONE SYNTHASE OR AROMATASE INHIBITOR
FGFR INHIBITOR FOR USE IN THE TREATMENT OF HYPOPHOSPHATEMIC DISORDERS
TYROSINE KINASE INHIBITOR COMBINATIONS AND THEIR USE
COMBINATION OF SOMATOSTATIN-ANALOGS WITH 11BETA-HYDROXYLASE INHIBITORS
PRESSURE RESPONSIVE DOWNHOLE TOOL HAVING A SELECTIVELY ACTIVATABLE PRESSURE RELIEF VALVE AND RELATED METHODS
NOVEL PHARMACEUTICAL COMPOSITION
COMBINATION THERAPY CONTAINING A PI3K-ALPHA INHIBITOR AND FGFR KINASE INHIBITOR FOR TREATING CANCER
PHARMACEUTICAL DOSAGE FORMS
COMBINED USE OF ANTI PD-1 AND ANTI M-CSF ANTIBODIES IN THE TREATMENT OF CANCER
USE OF THE IL-1BETA BINDING ANTIBODY CANAKINUMAB FOR TREATING OR ALLEVATING SYMPTOMS OF PULMONARY SARCOIDOSIS